Bank of New York Mellon
TXG icon

Bank of New York Mellon’s 10x Genomics TXG Stock Holding History

Bank of New York Mellon’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Buy
363,633
+16,071
+5% +$421K ﹤0.01% 1848
2026
Q1 		$7.38M Sell
347,562
-3,402
-1% -$68K ﹤0.01% 2091
2025
Q4 		$5.72M Sell
350,964
-27,939
-7% -$422K ﹤0.01% 2242
2025
Q3 		$4.43M Sell
378,903
-9,134
-2% -$119K ﹤0.01% 2390
2025
Q2 		$4.49M Buy
388,037
+102,113
+36% +$931K ﹤0.01% 2329
2025
Q1 		$2.5M Sell
285,924
-4,107
-1% -$51.8K ﹤0.01% 2580
2024
Q4 		$4.16M Sell
290,031
-45,337
-14% -$715K ﹤0.01% 2386
2024
Q3 		$7.57M Buy
335,368
+7,187
+2% +$149K ﹤0.01% 2077
2024
Q2 		$6.38M Sell
328,181
-522,634
-61% -$13.7M ﹤0.01% 2205
2024
Q1 		$31.9M Sell
850,815
-96,578
-10% -$4.24M 0.01% 1303
2023
Q4 		$53M Sell
947,393
-62,863
-6% -$2.74M 0.01% 1007
2023
Q3 		$41.7M Buy
1,010,256
+122,981
+14% +$6.4M 0.01% 1109
2023
Q2 		$49.5M Buy
887,275
+89,127
+11% +$4.82M 0.01% 1025
2023
Q1 		$44.5M Sell
798,148
-14,551
-2% -$679K 0.01% 1079
2022
Q4 		$29.6M Buy
812,699
+1,341
+0.2% +$43.8K 0.01% 1319
2022
Q3 		$23.1M Sell
811,358
-18,602
-2% -$709K 0.01% 1417
2022
Q2 		$37.6M Sell
829,960
-4,140
-0.5% -$215K 0.01% 1161
2022
Q1 		$63.5M Buy
834,100
+87,322
+12% +$7.64M 0.01% 942
2021
Q4 		$111M Sell
746,778
-7,127
-0.9% -$1.09M 0.02% 651
2021
Q3 		$110M Buy
753,905
+22,085
+3% +$3.79M 0.02% 632
2021
Q2 		$143M Sell
731,820
-66,799
-8% -$12.1M 0.03% 535
2021
Q1 		$145M Buy
798,619
+49,088
+7% +$8.48M 0.03% 530
2020
Q4 		$106M Buy
749,531
+101,766
+16% +$14.8M 0.02% 622
2020
Q3 		$80.8M Buy
647,765
+60,976
+10% +$6.4M 0.02% 666
2020
Q2 		$52.4M Buy
586,789
+123,031
+27% +$9.58M 0.01% 855
2020
Q1 		$28.9M Buy
463,758
+286,253
+161% +$22.3M 0.01% 1059
2019
Q4 		$13.5M Buy
177,505
+171,516
+2,864% +$10.3M ﹤0.01% 1807
2019
Q3 		$302K Buy
+5,989
New +$331K ﹤0.01% 3778

Other funds holding TXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

Bank of New York Mellon's TXG Position: Q2 2026 in Review

Bank of New York Mellon increased its 10x Genomics (TXG) stake by 4.6% in Q2 2026, buying an estimated $421K and bringing the position to 363,633 shares worth $13.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1848.

Bank of New York Mellon first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $145M in Q1 2021. 229 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Bank of New York Mellon held 363,633 shares of 10x Genomics worth $13.9M as of Q2 2026.
  • Bank of New York Mellon bought 16,071 10x Genomics shares in Q2 2026, an estimated $421K.
  • 10x Genomics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1848 holding.
  • Bank of New York Mellon first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • Bank of New York Mellon's 10x Genomics position peaked at $145M in Q1 2021.
  • 229 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.